Hepatitis c care at opioid clinics boosts treatment access

NCT ID NCT03155906

Completed Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether offering hepatitis C treatment at the same clinic where people receive opioid therapy leads to better outcomes than referring them to a separate infectious disease clinic. About 298 people on opioid therapy with chronic hepatitis C took part. The goal was to see if integrated care increases the number of people cured and improves treatment adherence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Integrated healthcare delivery (HCV treatment at opioid substitution therapy clinics)
What this could lead to: If this approach works, it could make hepatitis C treatment much easier for people on opioid therapy, leading to higher cure rates and fewer new infections.
What could go wrong: This is a completed trial, but the integrated model may not work in all settings or for all patients. Also, reinfection remains a risk if drug use continues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection hepatitis C virus infection opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C, CHRONIC OPIOID DEPENDENCE, ON AGONIST THERAPY

Contacts and locations

Locations

Department of Addiction Medicine, Haukeland University Hospital

Bergen, Hordaland, 5020, Norway
LAR Helse Stavanger HF

Stavanger, Rogaland, 4010, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.